IL-17A produced by αβ T cells drives airway hyper-responsiveness in mice and enhances mouse and human airway smooth muscle contraction. by Kudo, Makoto et al.
UCSF
UC San Francisco Previously Published Works
Title
IL-17A produced by αβ T cells drives airway hyper-responsiveness in mice and enhances 
mouse and human airway smooth muscle contraction.
Permalink
https://escholarship.org/uc/item/7vr1f7r9
Journal
Nature medicine, 18(4)
ISSN
1078-8956
Authors
Kudo, Makoto
Melton, Andrew C
Chen, Chun
et al.
Publication Date
2012-03-04
DOI
10.1038/nm.2684
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
IL-17A produced by αβ T cells drives airway hyper-
responsiveness in mice and enhances mouse and human airway 
smooth muscle contraction
Makoto Kudo1,2,3, Andrew C. Melton1,3, Chun Chen1, Mary B. Engler4, Katherine E. Huang1, 
Xin Ren1, Yanli Wang1, Xin Bernstein1, John T. Li1,5, Kamran Atabai1,6, Xiaozhu Huang1,7, 
and Dean Sheppard1,7
1Lung Biology Center, Department of Medicine, University of California, San Francisco, California, 
USA
2Department of Internal Medicine and Clinical Immunology, Yokohama City University, Graduate 
School of Medicine, Fukuura 3-9, Kanazawa, Yokohama 236-0004, Japan
4Department of Physiological Nursing, University of California, San Francisco
5Department of Pediatrics, University of California, San Francisco
6Cardiovascular Research Institute, University of California, San Francisco
Abstract
Emerging evidence suggests that the TH17 subset of αβ T cells contributes to the development of 
allergic asthma. In this study we found that mice lacking αvβ8 on dendritic cells failed to generate 
TH17 cells in the lung and were protected from AHR in response to house dust mite and 
ovalbumin sensitization and challenge. Because loss of TH17 cells inhibited airway narrowing 
without obvious effects on airway inflammation or epithelial morphology, we examined the direct 
effects of TH17 cytokines on mouse and human airway smooth muscle function. IL-17A enhanced 
contractile force generation through a NF-κB/RhoA/ROCK2 signaling cascade. Mice lacking 
integrin αvβ8 on dendritic cells showed impaired activation of this pathway after OVA 
sensitization and challenge, and the diminished contraction of tracheal rings from these mice was 
reversed by IL-17A. These data indicate that IL-17A produced by TH17 cells contributes to 
allergen-induced AHR through direct effects on airway smooth muscle.
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T helper 2 (TH2) cells are classically thought to mediate the development of asthma through 
the production of interleukin-4 (IL-4), IL-5, IL-9 and IL-131,2, but recent evidence suggests 
that the TH17-derived cytokine, IL-17A, may also play an important role3–5. T helper 17 
(TH17) cells are a pro-inflammatory T helper subset defined by production of IL-17A, 
IL-17F, and IL-22, and are thought to have evolved to aid in host defense against bacteria 
and fungi6. Elevated levels of IL-17A have been found in the serum, sputum and 
bronchoalveolar lavage fluids of patients with asthma and the IL-17A concentration found at 
these sites positively correlates with asthma severity7,8. Furthermore, genetic association 
studies with asthmatic patients have identified variations in several genes important for 
TH17 cell differentiation, including TGF-β19–11, IL-1β12, and IL-613. While TH17 cells 
appear to play a role in the development of allergic asthma, the mechanisms controlling their 
development in the lung are less clear.
Initial studies on TH17 differentiation showed that IL-6 and TGF-β are sufficient for the 
conversion of naïve T cells to TH17 cells14,15. The combination of TCR stimulation and 
TGF-β induces the synthesis of the retinoic acid-related orphan receptor gamma (RORγt) 
transcription factor, which is specific for the TH17 lineage among T cell subsets16. IL-6 
signaling triggers binding of STAT3 to the RORγt locus, resulting in a positive feedback 
loop that drives T cells toward the TH17 lineage17. More recent studies have shown that 
other stimuli, such as IL-1β, IL- 21, IL-23, commensal bacteria-derived ATP, segmented 
filamentous bacterium, and activators of the aryl hydrocarbon receptor, also promote TH17 
conversion or expand TH17 populations18–22. Still, TGF-β is a required factor for TH17 cell 
development in both humans and mice, and its regulation is likely a critical mechanism 
controlling the differentiation of TH17 cells22,23. TGF-β is produced as part of a latent 
complex and needs to be activated to bind TGF-β receptors24. We recently reported that 
integrin αvβ8 expressed on dendritic cells activates latent TGF-β and mediates the 
differentiation of both adaptive regulatory T cells and TH17 cells in the colon25,26. However, 
the relevance of this pathway for T cell differentiation in the lung and in the development of 
allergic airway disease has not been previously investigated.
Several activities of TH17 cells have been proposed as mechanisms for their role in 
promoting inflammation. IL-17A enhances neutrophil recruitment by stimulating bone 
marrow stromal cells to produce G-CSF, which augments granulopoiesis and the conversion 
of neutrophil progenitors from CD34+ cells27. IL-17A also induces neutrophil recruitment 
by stimulating the expression of CXCL1, CXCL2, CXCL5, and CXCL8 in epithelial cells28. 
Additional roles for IL-17A have been described. It promotes antibody isotype class 
switching in B cells and stimulates TH1-type immune responses by inducing macrophages to 
secrete IL- 12 29,30. While IL-17A is generally thought to serve a pro-inflammatory role in 
asthma through enhancement of neutrophil recruitment, additional roles for this and other 
TH17-derived cytokines in this disease remain largely unexplored.
In this study we began by determining the importance of integrin αvβ8 expressed on 
dendritic cells in a mouse model of allergic airway disease. Interestingly, we observed that 
these mice were protected from AHR without changes in lung inflammation and found that 
this protection correlated with a near-complete absence of lung TH17 cells. We therefore 
tested cytokines produced by TH17 cells for their ability to directly stimulate airway smooth 
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muscle hyper-contractility. Treatment of airway smooth muscle with IL-17A, but not IL-17F 
or IL-22, triggered enhanced tracheal ring contraction upon stimulation with MCh or KCl. 
Investigation into how IL-17A exerts this effect on airway smooth muscle revealed that 
IL-17A induces a NF-κB/RhoA/ROCK2 signaling cascade that results in increased myosin 
light chain phosphorylation after treatment with MCh. Tracheal rings isolated from OVA-
sensitized and challenged mice lacking integrin αvβ8 expressed on dendritic cells showed 
impaired activity of this signaling pathway, and treatment of tracheal rings with IL-17A 
completely restored OVA-induced hyper- contractility. These findings identify a critical role 
for the αvβ8 integrin on dendritic cells for generating pathogenic TH17 cells in allergic 
asthma and demonstrate, for the first time, that IL- 17A released from these cells contributes 
to airway hyperresponsiveness by directly increasing the contractility of airway smooth 
muscle.
RESULTS
Itgb8f/f x CD11c-cre mice are protected from AHR
To determine the role of integrin αvβ8 on dendritic cells in allergic airway disease, we 
sensitized and challenged control mice or mice lacking integrin αvβ8 on dendritic cells 
(Itgb8f/f x CD11c-cre mice) we have previously described25,26. In control mice, ovalbumin 
sensitization and challenge increased airway hyper-responsiveness (AHR) to the 
bronchoconstrictor, acetylcholine, but Itgb8f/f x CD11c-cre mice were significantly 
protected from allergen-induced AHR (Fig. 1a). To determine the mechanism for the 
diminished AHR seen in Itgb8f/f x CD11c-cre mice, we characterized mucus production and 
leukocyte accumulation in the lungs of these mice after OVA sensitization and challenge. 
Both control mice and Itgb8f/f x CD11c-cre mice showed similar numbers of mucus-
secreting cells by Periodic Acid-Schiff (PAS) staining, as well as similar numbers of 
macrophages, eosinophils, lymphocytes and polymorphonuclear cells in the bronchoalveolar 
lavage fluid (BAL) (Fig. 1b–d). We also examined whether Itgb8f/f x CD11c-cre mice were 
protected from AHR in the house dust mice (HDM) asthma model. Itgb8f/f x CD11c-cre 
mice had significantly reduced AHR after house dust mite sensitization and challenge 
(Supplementary Fig. 1a). Intranasal delivery of IL-13 is known to provoke AHR, mucus 
production and leukocyte accumulation in the lungs of mice2,31. We tested if Itgb8f/f x 
CD11c-cre mice were capable of developing AHR by administering IL-13 directly to the 
lungs. Treatment of Itgb8f/f x CD11c-cre mice with intranasal IL-13 resulted in similar AHR 
as control mice, indicating that Itgb8f/f x CD11c-cre mice have the capacity to develop AHR 
(Supplementary Fig. 1b).
Since AHR in response to OVA or HDM requires an adaptive immune response and our 
previous work implicates integrin αvβ8 on dendritic cells in the regulation of CD4+ T cell 
differentiation, we tested the recall response of lymphocytes to OVA and characterized the 
CD4+ T cell subsets in the lungs of these animals. Control and Itgb8f/f x CD11c-cre mice 
had similar lymphocyte recall responses to OVA (Fig. 1e). TH2 cells, identified by 
intracellular flow cytometry for IL-13, were increased similarly in control and Itgb8f/f x 
CD11c-cre mice (Fig. 1f,g). We found a small, but significant, decrease in the percentage of 
Foxp3+ adaptive regulatory T cells in the lungs of Itgb8f/f x CD11c-cre mice before OVA 
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sensitization and challenge, but there was no significant difference in the generation of 
regulatory T cells after OVA (Fig. 1f,g). OVA sensitization and challenge increased the 
percentage of TH17 cells, marked by expression of IL-17A and CD4, in the lungs of control 
mice, but Itgb8f/f x CD11c-cre mice had a near-absence of TH17 cells before and after OVA 
sensitization and challenge. Interestingly, the failure to generate IL-17A producing T cells in 
Itgb8f/f x CD11c-cre mice was restricted to the TH17 lineage, since the number of IL-17A 
producing γδ T cells in these mice was comparable to control mice (Fig. 1f,g). This finding 
suggests that Itgb8f/f x CD11c-cre mice may be protected from AHR through a specific 
defect in the generation of TH17 cells.
IL-17A enhances airway smooth muscle contraction
IL-13 and TNF-α are reported to act directly on airway smooth muscle to enhance AHR, 
and we wondered if IL-17 cytokines might also act in this fashion32,33. We first determined 
if IL-17 receptors were expressed on mouse airway smooth muscle cells. mRNA for both 
IL-17 receptor-A and IL-17 receptor-C was detected in cultured primary airway smooth 
muscle cells (Fig. 2a). We then determined the effects of IL-17A on the contractile force 
generated by mouse tracheal rings stimulated with methacholine (MCh) or depolarization 
with potassium chloride (KCl), and on the degree of airway narrowing induced by MCh in 
agarose-filled lung slices. IL-17A treatment alone had no effects on contraction when 
applied directly to tracheal rings in the organ bath for 15 minutes (data not shown). 
However, 12 hour incubation with IL-17A significantly enhanced both MCh and KCl-
induced tracheal ring contraction (Fig. 2b) and MCh-induced airway narrowing in lung 
slices (Fig. 2c,d). To determine if IL-17A was acting on the smooth muscle or epithelium, 
we denuded the epithelium from tracheal rings and measured the effects of IL-17A on 
contraction. As others have reported, epithelial removal enhanced the amount of force 
generation in response to MCh and KCl (Supplementary Fig. 2)34,35. In tracheal rings 
completely denuded of epithelium, IL-17A increased contraction to a similar degree as intact 
tracheal rings, indicating that IL-17A acts directly on smooth muscle to enhance contraction. 
We next determined whether IL-17A also enhanced airway smooth muscle contraction in 
humans. Human bronchi were isolated and incubated with IL-17A or carrier for 12 hours. 
As we observed with mouse tracheal rings, pretreatment with IL-17A significantly increased 
contraction of human bronchi in response to MCh and KCl (Fig. 2e). These data suggest that 
IL-17A acts on airway smooth muscle in mice and humans to enhance contractile responses.
We next performed a series of experiments to test whether IL-17A was interacting directly 
or indirectly with airway smooth muscle. Atropine, a muscarinic receptor antagonist, was 
added to tracheal rings to determine if IL-17A augmented contraction through modulation of 
MCh signaling. Atropine completely prevented contraction triggered by MCh in tracheal 
rings pretreated with IL-17A, but had no effect on contraction stimulated with KCl (Fig. 3a). 
We then confirmed that enhanced contraction was due to IL-17A and not other contaminants 
in our IL-17A preparation. Concurrent incubation with IL-17A and antibodies that block 
IL-17A activity prevented the enhanced contraction seen with IL-17A alone in response to 
MCh and KCl (Fig. 3b). TNF-α is known to enhance airway smooth muscle contraction and 
we wondered whether pretreatment with IL-17A was indirectly stimulating contractile 
responses through release of TNF-α33. TNF-α blocking antibodies had no effect on 
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enhanced tracheal ring contraction induced by IL-17A (Fig. 3c). To confirm that the TNF-α 
blocking antibodies were functional, we incubated tracheal rings with TNF-α in the presence 
or absence of TNF-α blocking antibodies. Pre-incubation with TNF-α increased tracheal 
ring contraction to both MCh and KCl and this enhancement was prevented with TNF-α 
blocking antibodies (Fig. 3d). These data indicate that IL-17A augments tracheal ring 
contraction through direct effects on airway smooth muscle.
IL-17A stimulates contraction through NF-κB, RhoA and ROCK2
Contractile force in airway smooth muscle is generated through actin-myosin cross-bridging 
and is regulated by myosin light chain (MLC) phosphorylation36. To determine if IL-17A 
enhances airway smooth muscle contraction through regulation of MLC-phosphorylation, 
we measured MLC-P with an antibody specific to phosphorylated Ser19 of MLC. IL-17A 
dramatically increased MCh-induced MLC Ser19 phosphorylation (Fig. 4a,b). IL-17A is 
reported to function through activation of nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB)37,38. To determine if IL-17A enhanced airway smooth muscle 
contraction through activation of NF-κB, we measured NF-κB activation in tracheal airway 
smooth muscle after treatment with 100 ng ml−1 IL-17A. IL-17A rapidly decreased the 
cytosolic concentration of NF-κB and subsequently induced nuclear translocation of NF-κB, 
indicating that IL-17A activates NF-κB in tracheal rings at a concentration that also 
promotes enhanced contraction (Fig. 4c,d). To determine whether IL-17A induced activation 
of NF-κB was required for enhanced contraction, we treated tracheal rings with the NF-κB 
small molecule inhibitor, BAY 11-7082. BAY 11-7082 dose-dependently reduced the 
IL-17A-mediated enhanced contractile response to both MCh and KCl (Fig. 4e). NF-κB is 
known to regulate expression of the small GTPase, RhoA and its effector kinases ROCK1 
and 239,40. The RhoA/ROCK signaling pathway is a critical mediator of airway smooth 
muscle contraction36,41. Treatment of tracheal rings with IL-17A increased expression of 
both RhoA and ROCK2, but not ROCK1 (Fig. 4f ,g). ROCK2 regulates MLC-
phosphorylation through phosphorylation of the myosin-binding subunit of myosin 
phosphatase (MYPT1), which inhibits the activity of myosin phosphatase42. IL-17A 
treatment of airway smooth muscle stimulated MYPT1 phosphorylation (Fig. 4f,g). To 
determine if the RhoA/ROCK2/MYPT1 pathway was required for IL-17A-mediated 
enhanced contraction, we blocked ROCK activity with the small molecule inhibitor 
Y-27632. Y-27632 inhibited IL-17A-mediated enhancement of tracheal ring contraction in a 
dose-dependent manner (Fig. 4h). To test whether stimulation of RhoA and ROCK2 
expression was mediated through NF-κB, we also measured expression of these proteins 
following treatment of tracheal rings with BAY 11-7082. Stimulation of tracheal rings with 
MCh after BAY 11-7082 treatment in the presence of IL-17A blocked increased expression 
of RhoA and resulted in decreased phosphorylation of MYPT1 and MLC (Fig. 4i). 
Treatment with Y-27632 under similar conditions had no effect on nuclear NF-κB 
translocation or RhoA expression, but as expected blocked phosphorylation of MYPT1 and 
MLC (Fig. 4i). We also determined if IL-17A regulated airway smooth muscle contraction 
through modulation of calcium signaling. Treatment of lung slices with IL-17A had no 
effect on methacholine-induced calcium wave oscillation amplitude or frequency 
(Supplementary Fig. 3). Collectively, these data indicate that IL-17A enhances contractile 
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responses of airway smooth muscle through activation of NF-κB and subsequent induction 
of RhoA and ROCK2 expression.
We explored if other cytokines produced by TH17 cells promote airway smooth muscle 
contraction. Incubation of tracheal rings with IL-17F or IL-22 for 12 hours at a range of 
doses (30–300 ng ml−1) had no significant effect on MCh or KCl-induced force generation 
(Fig. 5a,b). In contrast, incubation with IL-17A dose-dependently increased MCh or KCl-
induced force generation (Fig. 5b). Treatment with 100 ng ml−1 IL-17F and IL-22 followed 
by stimulation with MCh also had no effect on MLC phosphorylation, while IL-17A at this 
dose triggered a substantial increase (Fig. 5c). Since IL-17A and F both bind to the 
IL-17RA/RC heterodimer, we were surprised to see that IL-17F administered at three times 
the amount required for maximal effects of IL-17A still had no effect on airway smooth 
muscle contraction. Therefore, we confirmed that IL-17A enhanced airway smooth muscle 
contraction through binding to IL-17RA/RC. Tracheal rings isolated from mice deficient in 
IL-17RC failed to develop enhanced contraction upon IL-17A treatment and stimulation 
with MCh and KCl (Fig. 5d). Mice deficient in IL-17RC were also protected from AHR in 
the OVA sensitization and challenge model of allergic asthma, which provides further 
evidence that IL-17A is a critical factor for the development of AHR in this model (Fig. 5e).
To determine whether mice lacking integrin αvβ8 on dendritic cells were protected from 
AHR through impaired activation of an IL-17A induced NF-κB/RhoA/ROCK2 signaling 
cascade, we studied the activation of this pathway in OVA challenged control and Itgb8f/f x 
CD11c-cre mice. OVA sensitization and challenge induced a robust increase in NF-κB 
(nuclear), RhoA, ROCK2, p-MYPT1, and p-MLC in airway smooth muscle dissected from 
control mice, but had substantially reduced effects on each of these endpoints in airway 
smooth muscle from Itgb8f/f x CD11c-cre mice (Fig. 6a). Tracheal rings from OVA 
sensitized and challenged Itgb8f/f x CD11c-cre mice also had impaired contractile responses 
to both MCh and KCl (Fig. 6b). To test if a lack of IL-17A was responsible for the impaired 
contractile responses, we incubated tracheal rings from OVA sensitized and challenged 
control or Itgb8f/f x CD11c-cre mice with IL-17A. Pre-incubation of tracheal rings from 
OVA sensitized and challenged Itgb8f/f x CD11c-cre mice with IL-17A restored 
methacholine-induced force generation in a dose-dependent fashion to levels seen in control 
mice (Fig. 6c). Pre-incubation of tracheal rings from OVA sensitized and challenged control 
mice had only a minimal additional effect on contractility, probably because these tissues 
had already been exposed to IL-17A in vivo. These data suggest that mice lacking integrin 
αvβ8 on dendritic cells are protected from AHR as a consequence of reduced exposure of 
airway smooth muscle to IL-17A.
DISCUSSION
A growing body of evidence implicates TH17 cells and their associated cytokines in allergic 
asthma, especially in severe cases where inflammation is predominantly driven by 
neutrophils3,4. The data from this study indicate a novel mechanism for TH17 cells in 
asthma pathogenesis. We show for the first time that IL-17A enhances the contractile 
response of airway smooth muscle to MCh and KCl. Furthermore, we show that activation 
of latent TGF-β by integrin αvβ8 on dendritic cells is required for TH17 cell development in 
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the lung in response to sensitization and challenge with OVA and Alum. Interestingly, mice 
lackingαvβ8 on dendritic cells were protected from AHR without changes in inflammatory 
cell numbers, goblet cell differentiation, or lymphocyte recall responses, and were also 
protected from AHR in the house dust mite asthma model. Overall, these findings suggest 
that IL-17A can contribute to AHR through direct effects on airway smooth muscle, without 
grossly modulating airway inflammation or mucus metaplasia.
We performed a number of experiments to test if enhanced contraction provoked by IL-17A 
was due direct or indirect interactions between IL-17A and IL-17 receptors on airway 
smooth muscle. We depleted epithelium from tracheal rings by mechanical brushing to 
distinguish effects of IL-17A on epithelium and airway smooth muscle. Increased 
contraction was still observed in epithelium-denuded tracheal rings, which indicates that the 
effects of IL-17A on airway contractility do not depend on its known effects on airway 
epithelial cells. In line with previous reports, we saw that epithelial removal in and of itself 
was sufficient to enhance contractile responses of tracheal rings to MCh and KCl34,35, and 
we show here that this effect is potentiated further by pretreatment with IL-17A. We 
considered the possibility that a contaminant (e.g., LPS) in our IL-17A preparations might 
inadvertently stimulate contractile responses. However, enhanced contractile responses were 
completely prevented by adding IL-17A blocking antibodies, indicating that this result was 
due to the cytokine and not to contaminating factors. We also tested the specificity of 
IL-17A for its cognate receptor on airway smooth muscle. The IL-17 cytokine family signals 
through heterodimeric complexes of the IL-17 Receptor A (IL-17RA)-IL-17RE receptors, 
and IL-17A and F are known to bind the IL-17RA/RC heterodimer in other tissues28. We 
found that both of the IL-17RA/RC isoforms are expressed in airway smooth muscle and 
that enhanced contraction triggered by IL-17A was completely prevented in tracheal rings 
isolated from IL-17RC-deficient mice, and that these mice were protected from AHR 
induced by OVA sensitization and challenge. Collectively, these data indicate that IL-17A 
acts through IL-17RA/RC receptors expressed by airway smooth muscle to increase 
contractile responses. It was somewhat surprising that IL-17F, which like IL-17A can ligate 
IL-17RA/RC heterodimers, did not affect airway smooth muscle contractility over a range of 
concentrations that were sufficient to see the effects of IL-17A. We suspect that this result 
reflects the lower affinity of IL-17F for these receptors 43.
The NF-κB transcription factor is a major target of pro-inflammatory cytokines and we 
found in this study that IL-17A causes a robust activation of NF-κB upon MCh stimulation 
of airway smooth muscle. Since our primary phenotype after IL-17A treatment was 
enhanced contraction, we looked for NF-κB target genes that would modulate airway 
smooth muscle contraction. IL-17A treatment increased RhoA and ROCK2 expression, 
which are two prominent regulators of myosin light chain (MLC) phosphorylation and 
subsequent smooth muscle contraction36. Several groups have reported in studies of smooth 
muscle that activation of RhoA stimulates ROCK2 to phosphorylate myosin light chain 
phosphatase (MYPT)44–46. Phosphorylation deactivates MYPT and results in a net increase 
in MLC phosphorylation. Accordingly, our data show that IL-17A-induced expression of 
RhoA and ROCK2 correlated with enhanced phosphorylation of MLC and MYPT1. 
Phosphorylation of these proteins and expression of RhoA and ROCK2 was blocked with 
BAY 11-7082, a small molecule inhibitor of NF-κB, indicating that these proteins are target 
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genes of NF-κB. This pathway was also stimulated in airway smooth muscle of OVA 
sensitized and challenged mice, and was impaired in mice lacking integrin αvβ8 on dendritic 
cells. Furthermore, reduced tracheal ring contraction in OVA sensitized and challenged mice 
lacking integrin αvβ8 on dendritic cells could be completely restored by ex vivo IL-17A 
treatment. Together these data suggest that protection from AHR in mice lacking integrin 
αvβ8 on dendritic cells results from impaired IL-17A signaling. Since these mice had a near-
absence of pulmonary IL-17A producing αβ T cells (TH17), but minimal changes in IL-17A 
producing γδ T cells, our data suggest a model whereby IL-17A produced by TH17 cells acts 
on airway smooth muscle to induce AHR.
TH17 cells and IL-17A have been implicated in several mouse models of asthma, although 
some of these data are conflicting. Adoptive transfer of antigen-specific TCR transgenic T 
cells polarized in vitro to the Th17 phenotype into antigen challenged mice enhances AHR, 
as does pulmonary administration of an IL-17A overexpressing adenovirus47. Furthermore, 
as we observed in this study with IL-17RC-deficient mice, IL-17RA-deficient mice have 
been reported to show dramatic protection from AHR in an OVA sensitization and challenge 
model of allergic asthma48. However, this same study found that neutralization of IL-17A at 
the time of OVA challenge exacerbated AHR and local administration of IL-17A reduced 
eosinophilia and AHR. Another study using a similar model showed impaired induction of 
AHR in IL-17A-deficient mice crossed to OVA-specific TCR transgenic mice49. Several 
other studies that either neutralized IL-17A with antibodies or administered exogenous 
IL-17A have shown mixed effects on allergen-induced AHR, but the preponderance of 
evidence supports an important role for IL-17A in allergic airway inflammation50–53. It 
should be noted that the relative contributions of various cells and cytokines to models of 
allergic asthma can differ among inbred strains of mice, which might be one explanation for 
the apparently conflicting reports about the contributions of IL-17 to allergic asthma. Since 
all of the studies described in the current manuscript were performed in C57BL/6 mice, we 
cannot be certain that the same effects would be seen in other strains (e.g. Balb/c) in which 
TH2 cytokines have more potent effects. IL-17A was recently shown to act synergistically 
with IL-13 to enhance AHR in the A/J mouse strain, whereas the C3H/HeJ strain is naturally 
protected from AHR through decreased production of IL-17A5. Indeed, we and others have 
previously reported that inhibition of IL-13 can potently inhibit AHR in models of allergic 
asthma and that over-expression or administration of IL-13 is sufficient to induce AHR, in 
part through direct effects of IL-13 on airway epithelial cells. Based on the results of this 
study, we suspect transgenic or intranasal administration of IL-13 results in higher 
concentrations of IL-13 than those released in the context of allergen challenge, and that 
under those circumstances IL-17 is not required for the development of AHR. Although 
inhibitor studies confirm that released IL-13 is important in the development of allergen-
induced AHR, our results suggest that the small amounts of IL-13 released in response to 
allergen challenge are not in themselves sufficient to induce AHR, but require the additional 
effect of IL-17.
The results of this study provide several novel insights into how TH17 cells and TH17 
cytokines contribute to the development of allergic asthma, and thus identify a number of 
new potential therapeutic targets. Our results identify the integrin, αvβ8, as a critical 
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upstream activator that is essential for TH17 cell generation in allergic airway disease. We 
also show that loss of this integrin on dendritic cells dramatically inhibits TH17 cell 
generation without effects on the IL-17A producing γδ T cells, suggesting it might be 
possible to inhibit this TH17 induction without eliminating the key role played by IL-17A 
producing γδ T cells in pulmonary defense against bacterial and fungal pathogens. 
Furthermore, our findings are the first demonstration that IL-17A, but not IL-17F or IL-22, 
can contribute to allergic asthma by directly enhancing the contractile responses of airway 
smooth muscle cells, through a pathway that involves activation of NF-κB and induction of 
RhoA and ROCK2 expression. The αvβ8 integrin, IL-17A and NF-κB and its downstream 
effectors could thus all be attractive targets for improved treatment of allergic asthma.
METHODS
Mice
We generated mice lacking integrin β8 on DCs (Itgb8f/f x CD11c-cre) and mice deficient in 
IL-17RC (Il17rc
−/−) as previously described26,54. All mice were on the C57BL/6 
background and experiments were approved by the Institutional Animal Care and Use 
Committee of UCSF.
Allergen challenge models
We sensitized equal numbers of male and female 6–8 week old mice on days 0, 7, and 14 by 
intraperitoneal injection of 50 μg ovalbumin (OVA, Sigma-Aldrich) emulsified in 1 mg of 
aluminum potassium sulfate. One week after the lastsensitization, mice were intranasally 
challengedon 3 consecutive days with 100 μg OVA in 40 μL saline. Alternatively, 40 μL 
dust mite fecal pellet preparation (2.5 mg/ml, Greer Laboratories) or saline was administered 
intranasally on day 0, 7, 14 and 21. 24 hours after the last OVA challenge and 72 hours after 
the last HDM challenge, mice were attached to a pulmonary mechanics analyzer (FlexiVent; 
SIRAQ Inc, Canada), ventilated and paralyzed, and airway mechanics were measured in 
response to acetylcholine administered via tail vein.
We lavaged lungs five times with 0.8 ml of phosphate-buffered saline (PBS) and then 
inflated them with 10% buffered formalin to 25 cm H2O of pressure. Paraffin-embedded 5-
μm sections were stained with Periodic acid-Schiff (PAS) to evaluate mucus production. 
Antigen- specific lymphocyte proliferation was assessed by 3H-thymidine uptake.
Flow Cytometry
Single-cell suspensions were generated from whole lungs and incubated for 4 hours at 37o C 
in complete RPMI containing 50 ng/mL PMA (Sigma), 1 μM ionomycin (Sigma), and 2 μM 
monensin (eBioscience). Cells were then stained and analyzed as previously described25.
Tracheal ring contraction
Excised tracheas from male mice were cut into 3 mm rings, and placed in DMEM 
supplemented with 10mM HEPES and antibiotics. Rings were incubated with or without 
cytokines or antibodies for 12 hours in a 37o C incubator with 5% CO2. Rings were 
suspended in a 15-ml organ bath filled with oxygenated modified Krebs-Henseleit solution, 
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connected to a force-displacement transducer (FT03, Grass Instrument Co., West Warwick, 
RI) and a resting tension of 0.5 g was applied. After a 15 minute equilibration period, 
concentration-response curves to methacholine (MCh) and potassium chloride (KCl) were 
constructed.
We obtained human lung from a 66 year-old male lung transplant donor in accordance with 
procedures approved by the UCSFCommittee on Studies Involving Human Beings. Bronchi 
of 5 to 8 mm diameter were dissected free and cut into 4-mm-thick rings. We assessed 
contraction as above except a resting tension of 2 g was applied and rings were first 
contracted with 120 mM KCl after equilibration for 2 hours.
Airway contraction in lung slices
We prepared lung slices from 6–10 week old male mice based on the method developed by 
Bai and Sanderson55. Lungs were inflated with 1.0 ml of 2% agarose (37° C, low-melt 
preparative agarose) through a tracheal catheter. Air (0.2 ml) was injected to flush the 
agarose out of the airways. Lungs were cooled to 4° C and serial 140 μm sections were cut 
with a vibratome (model EMS-4000, EMS). Slices were maintained in DMEM 
supplemented with antibiotics at 37° C and 10% CO2 for up to 3 days. Images of whole lung 
slices were acquired using the area scan function and 5X objective on a temperature-
controlled Leica DM6000 inverted microscope at 37° C.
For measurement of calcium oscillations, lung slices were loaded with Oregon green 488 
BAPTA-AM (20 μM in HBSS containing 0.1% Pluronic F-127 and 100 μM 
sulfobromophthalein) for 45 min at 30° C and de-esterified for 30 min at 30° C in HBSS 
containing 100 μM sulfobromophthalein. Fluorescence imaging was performed with a 
NIKON spinning disk confocal microscope at 20 frames/second. Changes in fluorescence 
intensity from selected regions of interest (5 X 5 pixels) were analyzed with ImageJ 
software.
Western Blots
Smooth muscle was dissected from tracheas and homogenized in lysis buffer (50 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 1% (v/v) Nonidet P40, 10 mM NaF, 1 mM 
Na3VO4, and complete Mini protease inhibitor cocktail (Roche). TKM buffer (50 mM Tris-
HCl, pH 7.4, 25 mM KCl, 5 mM MgCl2) with 0.25 M Sucrose was used for nuclear extracts. 
Samples were separated by 10% SDS-PAGE, transferred to a polyvinylidene difluoride 
membrane (Millipore). Membranes were blocked for 30 min with 5% skim milk or BSA, 
incubated for 2 hours with primary antibodies, incubated for 1 hour with peroxidase-
conjugated secondary antibody and developed with Plus-ECL reagent (PerkinElmer).
Statistical Analysis
The statistical significance of differences between paired groups was calculated with a two-
tailed Student's t-test. One-way ANOVA was used for comparison of multiple groups using 
SigmaStat 3.11, and when differences were statistically significant (P≤0.05), this was 
followed with a Bonferroni t-test for subsequent pairwise analysis.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Itgb8f/f x CD11c-cre mice are protected from AHR and fail to develop Th17 cells in the 
lung
(a) Pulmonary resistance measurements after administration of acetylcholine in control and 
Itgb8f/f x CD11c-cre mice immunized and intranasally challenged with OVA or saline. Data 
are mean ± SEM values for 10–13 animals in each group. *P < 0.01 in Itgb8f/f x CD11c-cre 
mice compared to control mice. (b) PAS-stained lung sections from control and Itgb8f/f x 
CD11c-cre mice immunized and intranasally challenged with OVA or saline (scale bar = 50 
μm). (c) Quantitation of PAS-stained goblet cells from lung sections of control and Itgb8f/f x 
CD11c-cre mice immunized and intranasally challenged with OVA or saline. ***P < 0.001 
in OVA-treated control and Itgb8f/f x CD11c-cre mice compared to control and Itgb8f/f x 
CD11c-cre mice. PAS scores in OVA-treated Itgb8f/f x CD11c-cre mice are not statistically 
different from OVA-treated control mice (n=6 mice per group). (d) Total number of 
macrophages, eosinophils (Eos), lymphocytes (LC), and polymorphonuclear cells (PMN) 
counted in the BAL of control and Itgb8f/f x CD11c-cre mice immunized and intranasally 
challenged with OVA or saline. *P < 0.05, **P < 0.01 and ***P < 0.001 in OVA-treated 
control and Itgb8f/f x CD11c-cre samples compared to saline-treated control and Itgb8f/f x 
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CD11c-cre samples. Eosinophil counts from OVA-treated Itgb8f/f x CD11c-cre samples 
were not statistically significant (N.S) compared to saline-treated Itgb8f/f x CD11c-cre 
samples. None of the Itgb8f/f x CD11c-cre groups are statistically different from control 
mice (n=8–13 mice per group). (e) Measurement of incorporated 3H-thymidine upon re-
exposure to OVA in lymphocytes isolated from the lungs of control and Itgb8f/f x CD11c-
cre mice immunized and intranasally challenged with OVA. (f) Flow cytometry plots of 
CD4+ and γδ+ T cells isolated from the lungs of control and Itgb8f/f x CD11c-cre mice 
immunized and intranasally challenged with OVA or saline. Cells were activated with PMA 
and Ionomycin and then stained for IL-13, Foxp3, and IL-17A. The top and middle panels 
show CD4+ gated cells, and the bottom panels show γδ+ gated cells. (g) Percentage of IL-13, 
Foxp3, or IL-17A positive CD4+ T cells and IL-17A positive γδ+ T cells isolated from the 
lungs of control and Itgb8f/f x CD11c-cre mice immunized and intranasally challenged with 
OVA or saline. *P < 0.01 and **P < 0.001 in Itgb8f/f x CD11c-cre mice compared to control 
mice.
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Figure 2. IL-17A enhances mouse and human airway smooth muscle contraction
(a) RT-PCR products after amplification with primers to Il17ra, Il17rc, and Gapdh and 
RNA isolated from whole lung or primary airway smooth muscle cells cultured from 2 
different mice. Reactions without cDNA were used as a negative control. (b) Contractile 
force measurements from mouse tracheal rings treated for 12 hours with or without 100 ng 
ml−1 IL-17A and stimulated with methacholine (MCh) or potassium chloride (KCl). Data 
are means ± SEM of at least 5 tracheal rings per group. (c) Phase contrast images of lung 
slices treated for 12 hours with or without 100 ng ml−1 IL-17A and stimulated with saline or 
MCh for 10 minutes (scale bar = 100 μm). (d) Measurement of the % lumen area change of 
airways in lung slices treated for 12 hours with or without 100 ng ml−1 IL-17A and 
stimulated with saline or MCh for 10 minutes. (e) Contractile force measurements from 
human bronchi treated for 12 hours with or without 100 ng ml−1 human IL-17A (hIL-17A) 
and stimulated with methacholine (MCh) or potassium chloride (KCl). *P < 0.05 and **P < 
0.001 in IL-17A treated samples compared to control samples.
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Figure 3. IL-17A-mediated enhanced ASM contraction is not due to contaminants or TNF-α 
release
(a) Contractile force measurements from mouse tracheal rings treated for 12 hours with or 
without 100 ng ml−1 IL-17A in the presence of 1μM atropine and stimulated with 
methacholine MCh or KCl. (b) Contractile force measurements from tracheal rings 
stimulated with MCh or KCl after treatment for 12 hours with or without 100 ng ml−1 
IL-17A in the presence of 40 μg ml−1 IL-17 neutralizing antibodies or isotype control 
antibodies. (c) Contractile force measurements from tracheal rings stimulated with MCh or 
KCl after treatment for 12 hours with or without 100 ng ml−1 IL-17A in the presence of 40 
μg ml−1 TNF-α neutralizing antibodies or isotype control antibodies. (d) Contractile force 
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measurements from tracheal rings stimulated with MCh or KCl after treatment for 12 hours 
with or without 100 ng ml−1 TNF-α in the presence of 40 μg ml−1 TNF-α neutralizing 
antibodies or isotype control antibodies. *P < 0.05, **P < 0.01 and ***P < 0.001 in IL-17A 
or TNF-α treated samples compared to control samples.
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Figure 4. NF-κB/RhoA/ROCK2 signaling facilitates the effects of IL-17A on enhanced ASM 
contraction
Tracheal smooth muscle samples were treated with 100 ng ml−1 IL-17A for 12 hours and 1 
mM MCh for 15 minutes. Samples were then lysed, separated by SDS-PAGE and 
transferred to a membrane. Membranes were probed with antibodies to Ser-19 
phosphorylated MLC, total MLC, and GAPDH (a), nuclear and cytosolic NF-κB, Histone 
H1, and GAPDH (c), RhoA, ROCK1, ROCK2, GAPDH, phosphorylated MYPT1, and total 
MYPT1 (f). Samples isolated from 4 mice are shown. All blots were stripped and re-probed 
to ensure equal amounts of protein were loaded in each well. Blots were analyzed with 
densitometry to determine the relative amounts of Ser-19 phosphorylated MLC (b), nuclear 
and cytosolic NF-κB (d), and RhoA, ROCK1, ROCK2, and phosphorylated MYPT1 (g). 
Tracheal rings were treated for 12 hours with or without 100 ng ml−1 IL-17A and BAY 
11-7082 (0, 5, 10 and 20 μM; e) or Y27632 (0, 0.1, 10, and 100 μM; h). Contractile force 
measurements were then made in response to stimulation with 1 mM MCh or 60 mM KCl. 
(i) Tracheal smooth muscle samples were treated with 100 ng ml−1 IL-17A for 12 hours and 
1 mM MCh for 15 minutes in the presence of the indicated doses of BAY 11-7082 or 
Y27632. Samples were then handled as described above to detect nuclear NF-κB, RhoA, 
phosphorylated MYPT1, total MYPT1, Ser-19 phosphorylated MLC, and total MLC. Blots 
were stripped and re-probed with either Histone H1 or GAPDH to ensure equal amounts of 
protein were loaded in each well. *P < 0.05, **P < 0.01 and ***P < 0.001 in IL-17A treated 
samples compared to control samples.
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Figure 5. IL-17F and IL-22 do not enhance ASM contraction, and IL-17A requires IL-17RC
(a) Contractile force measurements from tracheal rings treated for 12 hours with or without 
100 ng ml−1 IL-17F or IL-22 and stimulated with MCh or KCl. (b) Dose-response curves of 
tracheal rings treated for 12 hours with or without increasing doses of IL-17A, IL-17F or 
IL-22 and stimulated with 1 mM MCh or 60 mM KCl. *P < 0.05 in IL-17A treated samples 
compared to control, IL-17F, or IL-22 treated samples. (c) Tracheal smooth muscle samples 
were treated with 100 ng ml−1 IL-17A, IL-17F, or IL-22 for 12 hours and 1 mM MCh for 15 
minutes. Samples were then lysed, separated by SDS-PAGE, transferred to a membrane, and 
probed with antibodies to Ser-19 phosphorylated MLC, total MLC, and GAPDH. (d) 
Contractile force measurements from tracheal rings isolated from control or Il17rc−/− mice 
treated for 12 hours with or without 100 ng ml−1 IL-17A and stimulated with increasing 
doses of MCh or KCl. *P < 0.05 and **P < 0.01 in IL-17A treated control samples 
compared to Il17rc−/− mice. (e) Pulmonary resistance measurements after administration of 
acetylcholine in control and Il17rc−/− mice immunized and intranasally challenged with 
OVA or saline. *P < 0.05 in OVA treated control mice compared to OVA treated Il17rc−/− 
mice.
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Figure 6. Impaired IL-17A signaling mediates the protection of Itgb8f/f x CD11c-cre mice from 
AHR
(a) Western blots were prepared as described in Figure 3 with tracheal smooth muscle 
samples isolated from control and Itgb8f/f x CD11c-cre mice immunized with saline or 
OVA. Lysates from 5 individual mice in the saline immunized groups and lysates from 6 
individual mice in the OVA immunized groups are shown. Blots were stripped and re-
probed with either Histone H1 or GAPDH to ensure equal amounts of protein were loaded in 
each well. (b) Contractile force measurements from tracheal rings isolated from control and 
Itgb8f/f x CD11c-cre mice immunized with saline or OVA and treated for 12 hours with or 
without 100 ng ml−1 IL-17A followed by stimulation with MCh or KCl. *P < 0.05, **P < 
0.01 and ***P < 0.001 in IL-17A treated samples from control mice compared to control 
samples (above) or IL-17A treated samples from Itgb8f/f x CD11c-cre mice compared to 
control samples (below). (c) Contractile force measurements in tracheal rings isolated from 
OVA immunized control and Itgb8f/f x CD11c-cre mice and treated with the indicated 
concentrations of IL-17A for 12 hours followed by stimulation with 1 mM MCh or 60 mM 
KCl. *P < 0.05 and **P < 0.01 in IL-17A treated samples from control mice compared to 
IL-17A treated samples from Itgb8f/f x CD11c-cre mice.
Kudo et al. Page 21
Nat Med. Author manuscript; available in PMC 2012 October 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
